osimertinib-话题@MedSci

#osimertinib#

17篇内容 | 1713人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2273989, encodeId=199122e39890c, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=CA Cancer J Clin：EGFR突变非小细胞肺癌——从早期到晚期疾病的个性化管理新进展, objectType=article, longId=887279, objectId=28b288e27968, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250122/1737522567541_8538692.png, objectUrl=/article/show_article.do?id=28b288e27968, replyNumber=0, likeNumber=15, createdTime=2025-07-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=28b288e27968, moduleTitle=CA Cancer J Clin：EGFR突变非小细胞肺癌——从早期到晚期疾病的个性化管理新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28b288e27968)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2273297, encodeId=63f822e3297ca, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a> EGFR基因的激活性突变，尤其是19号外显子缺失（Ex19del）及21号外显子L858R点突变在NSCLC患者中占多数，约85%-90%。三代EGFR-TKI如osimertinib及lazertinib已被证实优于早期一代药物，提高PFS和安全性。Osimertinib是全球广泛应用的标准治疗，但伴随心脏毒性等安全问题的报道逐渐增多。Lazertinib是一款高选择性且有效通过血脑屏障的三代EGFR-TKI，对野生型EGFR毒性相对较低，尤其对心脏QT间期延长的影响较小，理论基础更稳固。, objectTitle=osimertinib, objectType=topic, longId=13501, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=2, createdTime=2025-07-14, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2273289, encodeId=54a722e3289f8, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a> <a href='/topic/show?id=a89910e255e' target=_blank style='color:#2F92EE;'>#lazertinib#</a> <a href='/topic/show?id=253b12856035' target=_blank style='color:#2F92EE;'>#EGFR突变晚期非小细胞肺癌#</a>, objectTitle=Lazertinib Vs Osimertinib：MARIPOSA研究探索EGFR突变晚期非小细胞肺癌初治患者的疗效和安全性比较, objectType=article, longId=886555, objectId=ed7188655534, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250122/1737525065730_8538692.png, objectUrl=/article/show_article.do?id=ed7188655534, replyNumber=0, likeNumber=29, createdTime=2025-07-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ed7188655534, moduleTitle=Lazertinib Vs Osimertinib：MARIPOSA研究探索EGFR突变晚期非小细胞肺癌初治患者的疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7188655534)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2223797, encodeId=6eac2223e9796, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a> <a href='/topic/show?id=a89910e255e' target=_blank style='color:#2F92EE;'>#lazertinib#</a> <a href='/topic/show?id=15611080035b' target=_blank style='color:#2F92EE;'>#amivantamab#</a> <a href='/topic/show?id=648d118539fc' target=_blank style='color:#2F92EE;'>#WCLC 2024#</a>, objectTitle=WCLC 2024 ：Amivantamab联合Lazertinib对比Osimertinib一线治疗EGFR突变NSCLC展现更优疗效（MARIPOSA研究）, objectType=article, longId=841653, objectId=6f9c841653a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240902/1725290369209_8624274.png, objectUrl=/article/show_article.do?id=6f9c841653a4, replyNumber=0, likeNumber=123, createdTime=2024-09-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6f9c841653a4, moduleTitle=WCLC 2024 ：Amivantamab联合Lazertinib对比Osimertinib一线治疗EGFR突变NSCLC展现更优疗效（MARIPOSA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f9c841653a4)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1464208, encodeId=73e614642080b, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, objectType=article, longId=295378, objectId=2fbf2953e8d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbf2953e8d9, replyNumber=0, likeNumber=102, createdTime=2022-02-11, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbf2953e8d9, moduleTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fbf2953e8d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464207, encodeId=9ef3146420e87, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, objectType=article, longId=204599, objectId=0719204599a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0719204599a7, replyNumber=0, likeNumber=111, createdTime=2020-12-18, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0719204599a7, moduleTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0719204599a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464206, encodeId=f7701464206a1, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查, objectType=article, longId=202339, objectId=864620233978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864620233978, replyNumber=0, likeNumber=99, createdTime=2020-10-22, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864620233978, moduleTitle=阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864620233978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464205, encodeId=61ca1464205d0, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=抑癌基因疗法Oncoprex与Osimertinib联合治疗非小细胞肺癌（NSCLC）, objectType=article, longId=187589, objectId=add618e5896e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=add618e5896e, replyNumber=0, likeNumber=106, createdTime=2020-02-08, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=add618e5896e, moduleTitle=抑癌基因疗法Oncoprex与Osimertinib联合治疗非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=add618e5896e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464204, encodeId=45e814642045e, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=NEJM：Osimertinib一线治疗晚期非小细胞肺癌, objectType=article, longId=185953, objectId=3ac51859536b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ac51859536b, replyNumber=0, likeNumber=81, createdTime=2020-01-10, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ac51859536b, moduleTitle=NEJM：Osimertinib一线治疗晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ac51859536b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464203, encodeId=7abc14642038a, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性, objectType=article, longId=185754, objectId=cd71185e5469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd71185e5469, replyNumber=0, likeNumber=108, createdTime=2020-01-07, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd71185e5469, moduleTitle=J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd71185e5469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464202, encodeId=b449146420293, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌, objectType=article, longId=178988, objectId=c2d11e898883, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2d11e898883, replyNumber=0, likeNumber=89, createdTime=2019-09-07, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2d11e898883, moduleTitle=NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2d11e898883)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464201, encodeId=07e7146420118, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制, objectType=article, longId=156361, objectId=58b8156361b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b8156361b3, replyNumber=0, likeNumber=134, createdTime=2018-12-23, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b8156361b3, moduleTitle=CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b8156361b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464200, encodeId=35b8146420043, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, objectType=article, longId=147673, objectId=4a4a14e6733c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4a14e6733c, replyNumber=0, likeNumber=152, createdTime=2018-08-31, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4a14e6733c, moduleTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4a14e6733c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464199, encodeId=a211146419923, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=CLIN CANCER RES：非小细胞肺癌患者Osimertinib耐药机制, objectType=article, longId=142571, objectId=bb831425e113, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb831425e113, replyNumber=0, likeNumber=127, createdTime=2018-07-07, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb831425e113, moduleTitle=CLIN CANCER RES：非小细胞肺癌患者Osimertinib耐药机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb831425e113)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464198, encodeId=34f31464198a6, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=JCO：Osimertinib比化疗有利于改善晚期非小细胞肺癌患者的状态, objectType=article, longId=138007, objectId=835513800e98, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=835513800e98, replyNumber=0, likeNumber=119, createdTime=2018-05-14, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=835513800e98, moduleTitle=JCO：Osimertinib比化疗有利于改善晚期非小细胞肺癌患者的状态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=835513800e98)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464197, encodeId=9130146419e67, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=EUR J Cancer：需对Osimertinib诱导的QT延长严加防范, objectType=article, longId=130731, objectId=51d5130e315f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51d5130e315f, replyNumber=0, likeNumber=116, createdTime=2018-02-28, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51d5130e315f, moduleTitle=EUR J Cancer：需对Osimertinib诱导的QT延长严加防范, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51d5130e315f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464196, encodeId=26eb14641963e, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请, objectType=article, longId=122074, objectId=1ca11220e4f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ca11220e4f0, replyNumber=0, likeNumber=94, createdTime=2017-12-03, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ca11220e4f0, moduleTitle=欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ca11220e4f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464195, encodeId=ed3f1464195dd, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, objectType=article, longId=93392, objectId=9692933925e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9692933925e, replyNumber=0, likeNumber=94, createdTime=2017-03-27, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9692933925e, moduleTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9692933925e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464194, encodeId=938214641945a, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布, objectType=article, longId=81116, objectId=25a48111657, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25a48111657, replyNumber=0, likeNumber=69, createdTime=2016-10-28, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25a48111657, moduleTitle=2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25a48111657)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464193, encodeId=587a14641931f, content=<a href='/topic/show?id=4f2113501a7' target=_blank style='color:#2F92EE;'>#osimertinib#</a>, objectTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, objectType=article, longId=73238, objectId=b19de323897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b19de323897, replyNumber=0, likeNumber=106, createdTime=2016-07-21, rootId=0, userName=dongjia2012, userId=126d6614911, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b19de323897, moduleTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b19de323897)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

osimertinib

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #osimertinib#

CA Cancer J Clin：EGFR突变非小细胞肺癌——从早期到晚期疾病的个性化管理新进展

2025-07-19发表于上海

yangchou (审核中...)

前往app查看评论内容

全文收起 #osimertinib# EGFR基因的激活性突变，尤其是19号外显子缺失（Ex19del）及21号外显子L858R点突变在NSCLC患者中占多数，约85%-90%。三代EGFR-TKI如osimertinib及lazertinib已被证实优于早期一代药物，提高PFS和安全性。Osimertinib是全球广泛应用的标准治疗，但伴随心脏毒性等安全问题的报道逐渐增多。Lazertinib是一款高选择性且有效通过血脑屏障的三代EGFR-TKI，对野生型EGFR毒性相对较低，尤其对心脏QT间期延长的影响较小，理论基础更稳固。

2025-07-14发表于浙江省

梅斯管理员 (审核中...)

前往app查看评论内容

#osimertinib# #lazertinib# #EGFR突变晚期非小细胞肺癌#

Lazertinib Vs Osimertinib：MARIPOSA研究探索EGFR突变晚期非小细胞肺癌初治患者的疗效和安全性比较

2025-07-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #osimertinib# #lazertinib# #amivantamab# #WCLC 2024#

WCLC 2024 ：Amivantamab联合Lazertinib对比Osimertinib一线治疗EGFR突变NSCLC展现更优疗效（MARIPOSA研究）

2024-09-03发表于上海

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后

2022-02-11

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用

2020-12-18

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查

2020-10-22

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

抑癌基因疗法Oncoprex与Osimertinib联合治疗非小细胞肺癌（NSCLC）

2020-02-08

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

NEJM：Osimertinib一线治疗晚期非小细胞肺癌

2020-01-10

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性

2020-01-07

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

NMPA授予Tagrisso（osimertinib）上市许可，治疗EGFR突变的非小细胞肺癌

2019-09-07

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

CLIN CANCER RES：Osimertinib治疗EGFR突变非小细胞肺癌的耐药机制

2018-12-23

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应

2018-08-31

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

CLIN CANCER RES：非小细胞肺癌患者Osimertinib耐药机制

2018-07-07

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

JCO：Osimertinib比化疗有利于改善晚期非小细胞肺癌患者的状态

2018-05-14

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

EUR J Cancer：需对Osimertinib诱导的QT延长严加防范

2018-02-28

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

欧洲药品管理局已经接受了Tagrisso（osimertinib）营销授权申请

2017-12-03

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批

2017-03-27

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

2016NICE技术评估指南：osimertinib用于治疗局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌（TA416）发布

2016-10-28

dongjia2012 (审核中...)

前往app查看评论内容

#osimertinib#

第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功

2016-07-21

科室
- - 订阅+
  - 更多科室
工具
服务